ResMed (RMD) Expected to Announce Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is expected to be releasing its earnings data after the market closes on Thursday, January 30th. Analysts expect ResMed to post earnings of $2.29 per share and revenue of $1.27 billion for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

ResMed Stock Performance

NYSE:RMD opened at $250.03 on Wednesday. The company has a market cap of $36.70 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 1.78 and a beta of 0.70. The stock has a fifty day moving average price of $239.56 and a 200-day moving average price of $235.40. ResMed has a fifty-two week low of $170.56 and a fifty-two week high of $260.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92.

Insider Buying and Selling at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the sale, the director now owns 83,204 shares of the company’s stock, valued at approximately $20,696,162.96. This represents a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Witte Jan De sold 796 shares of ResMed stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the transaction, the director now directly owns 6,723 shares in the company, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,099 shares of company stock worth $2,719,385. 0.71% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

RMD has been the topic of several analyst reports. Robert W. Baird increased their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Stifel Nicolaus assumed coverage on ResMed in a research note on Friday, December 13th. They issued a “hold” rating and a $250.00 price target on the stock. The Goldman Sachs Group initiated coverage on ResMed in a research report on Thursday, January 16th. They set a “buy” rating for the company. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ResMed in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $238.40.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.